{"entity":{"id":"vedolizumab","kind":"drug","name":"Vedolizumab","aka":[],"tldr":"Vedolizumab is a gut-targeted anti-inflammatory drip for ulcerative colitis and Crohn's disease, used when colitis caused by checkpoint immunotherapy does not settle with steroids and infliximab.","summary":"The Entyvio label covers moderately to severely active ulcerative colitis and Crohn's disease in adults. SITC 2021: if colitis symptoms persist after the second infliximab dose, \"the third dose should be held and 3 doses of vedolizumab (300 mg) should be administered at 0, 2, and 6 weeks\" (LE 1); SITC notes that vedolizumab blocks alpha-4 beta-7 integrin, giving gut-selective anti-inflammatory activity. The use for immune-related colitis is off-label. The BLA was first approved on 20 May 2014.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Vedolizumab","links":[{"label":"US label (DailyMed): Entyvio","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c"},{"label":"Brahmer et al., SITC clinical practice guideline on immune checkpoint inhibitor-related adverse events (J Immunother Cancer 2021)","url":"https://doi.org/10.1136/jitc-2021-002435"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["infliximab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["immune-colitis","irae"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Entyvio","modality":"Monoclonal antibody (gut-selective integrin receptor antagonist)","supportive":true,"mechanism":"A monoclonal antibody against alpha-4 beta-7 integrin that blocks immune cell traffic into the gut, giving a gut-selective anti-inflammatory effect.","approvals":[{"region":"US","year":2014,"indication":"Moderately to severely active ulcerative colitis and Crohn's disease in adults","note":"Year is the original BLA 125476 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vedolizumab/","neighbours":{"drug":[{"id":"infliximab","kind":"drug","name":"Infliximab","route":"/drugs/infliximab/"}],"term":[{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"}]}}